SHB.B

216.8

+2.85%↑

SWED.A

323.4

+0.84%↑

SCA.A

124.9

+0.77%↑

EVO

602

+4.48%↑

SKF.B

230.5

+3.27%↑

SHB.B

216.8

+2.85%↑

SWED.A

323.4

+0.84%↑

SCA.A

124.9

+0.77%↑

EVO

602

+4.48%↑

SKF.B

230.5

+3.27%↑

SHB.B

216.8

+2.85%↑

SWED.A

323.4

+0.84%↑

SCA.A

124.9

+0.77%↑

EVO

602

+4.48%↑

SKF.B

230.5

+3.27%↑

SHB.B

216.8

+2.85%↑

SWED.A

323.4

+0.84%↑

SCA.A

124.9

+0.77%↑

EVO

602

+4.48%↑

SKF.B

230.5

+3.27%↑

SHB.B

216.8

+2.85%↑

SWED.A

323.4

+0.84%↑

SCA.A

124.9

+0.77%↑

EVO

602

+4.48%↑

SKF.B

230.5

+3.27%↑

Search

Cloetta AB

Aperta

53.2

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

52.85

Massimo

53.9

Metriche Chiave

By Trading Economics

Entrata

109M

298M

Vendite

54M

2.2B

P/E

Media del settore

18.13

54.484

EPS

0.8

Rendimento da dividendi

2.79

Margine di Profitto

13.357

Dipendenti

2,614

EBITDA

50M

389M

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.79%

4.92%

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.8B

14B

Apertura precedente

53.2

Chiusura precedente

53.2

Cloetta AB Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 mar 2026, 23:31 UTC

Azioni calde

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Utili

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr 2026, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Acquisizioni, Fusioni, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Utili

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Discorsi di Mercato
Utili

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Discorsi di Mercato

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Utili

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Utili

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Acquisizioni, Fusioni, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Discorsi di Mercato

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Utili

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Utili

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Utili

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Utili

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Utili

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Utili

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Utili

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Utili

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Discorsi di Mercato
Utili

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Utili

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Utili

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Utili

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Utili

Nike CEO: Converse Remains Important to Portfolio

Confronto tra pari

Modifica del prezzo

Cloetta AB Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cloetta AB

Cloetta AB (publ) operates as a confectionary company. It operates through Branded Packaged Products and Pick & Mix segments. The company manufactures and markets chocolate confectionery products, including pralines, chocolate wafers, dragees, plates, and countlines under the Kexchoklad, Polly, Plopp, Tupla, Royal, Sportlunch, Bridge, Lonka, Sinas, and Snippers brands. It also provides confectionery products comprising foams, wine gums, liquorice, toffees, hard boiled candies, and lollypops under the Malaco, Red Band, Ahlgrens bilar, Venco, Chewits, and Juleskum brands. In addition, the company offers pastilles under the Läkerol, Mynthon, and King brands, as well as chewing gums under the Jenkki, Sportlife, and Xylifresh brands. Further, it produces and sells dry roasted nuts under the Nutisal brand. The company sells its products through a network of grocery retail trade, service trade, e-commerce, and other sales channels in Sweden, Finland, the Netherlands, Denmark, Norway, Germany, the United Kingdom, and internationally. Cloetta AB (publ) was founded in 1862 and is headquartered in Sundbyberg, Sweden.
help-icon Live chat